Artiva Biotherapeutics, Inc. Common Stock

10-Year Study

ARTV.US · Healthcare · US · Common Stock

Executive Summary: Artiva Biotherapeutics, Inc. Common Stock has compounded at 1.5% annually over the last 10 years, with a maximum drawdown of 90.2% and an annualized volatility of 483.0%.

1Y CAGR
+640.6%
3Y CAGR
+1.5%
5Y CAGR
+1.5%
10Y CAGR
+1.5%

History & Riski10-year historical performance analysis including CAGR, Max Drawdown, Sharpe & Sortino ratios, annual returns, and rolling volatility — all computed from daily market data.

10-Year Growth of $10,000

Max DrawdownMax DrawdownThe largest peak-to-trough decline in the asset's value over the measurement period.Click for full definition →
90.2%
Sharpe RatioSharpe RatioRisk-adjusted return: how much excess return you earn per unit of total risk (volatility).Click for full definition →
0.74
Sortino RatioSortino RatioLike Sharpe, but only penalizes downside volatility — a more accurate risk measure for asymmetric return distributions.Click for full definition →
2.24
Ann. VolatilityAnnualized VolatilityThe annualized standard deviation of an asset's returns — a measure of how much prices fluctuate.Click for full definition →
134.4%
Best YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2026 · +182.3%
Worst YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2025 · -57.4%
% Positive Years% Positive YearsThe percentage of calendar years in the measurement period where the asset delivered a positive return.Click for full definition →
50%

Annual Returns

Rolling 12-Month Returns

Rolling 12-Month Annualised Volatility

Historical Drawdowns

Monthly Returns

Monthly Returns Heatmap

YearJanFebMarAprMayJunJulAugSepOctNovDecAnn.
2026-9.349.610.788.0————————182.3%
2025-49.6-18.3-27.7-20.3-19.2-21.898.75.0-8.945.3-9.814.1-57.4%
2024———————-2.233.9-34.426.0-21.1-14.6%

Risk X-RayiA 19-factor macroeconomic risk decomposition showing exactly which market forces (equity beta, rates, inflation, credit, commodity, crypto) drive this asset's volatility. Powered by multivariate regression against daily factor returns.

Risk Profile Insight: This asset has an estimated annualized volatility of 483.0%. The dominant macroeconomic risk driver is LQD.US, accounting for 19.9% of variance. Idiosyncratic stock-specific factors contribute 1.7%.

10-Year Historical Price Series (Growth of $10,000)
DateSimulated Value
2024-07-0110000
2024-08-019779.660826543051
2024-09-0113093.219965704902
2024-10-018593.220491033966
2024-11-0110830.508073216646
2024-12-018542.372678621377
2025-01-014305.084611519561
2025-02-013516.949176514364
2025-03-012542.37284026109
2025-04-012025.42378497651
2025-05-011635.5931494503807
2025-06-011279.660988182763
2025-07-012542.37284026109
2025-08-012669.491563094001
2025-09-012432.2032535326157
2025-10-013533.8983126188
2025-11-013186.440618378581
2025-12-013635.5931292454165
2026-01-013296.610205107055
2026-02-014932.203310106515
2026-03-015457.62703042714
2026-04-0110262.7116985206
Annual Return Matrix
YearAnnual Return
2025-0.5744047624679199
20261.8228438479447426
Total Factor Risk
4.830362972570914
VTI.US Exposure
0.13128100438283682
VEA.US Exposure
0.008296111125915554
VWO.US Exposure
0.002688180192493674
QQQ.US Exposure
0.03517015429577634
VTV.US Exposure
0.13753314781745948
IJR.US Exposure
0.016473266843767865
QUAL.US Exposure
0.03159344858006504
SHV.US Exposure
0.1784556952665272
TLT.US Exposure
0.0016333937256493803
LQD.US Exposure
0.19940264721633766
HYG.US Exposure
0.185916903850401
GLD.US Exposure
-0.0008532783245915076
USO.US Exposure
-0.0001967129483038786
VNQ.US Exposure
0.004373081251348855
BTC-USD.CC Exposure
0.0034458525457917557
CPER.US Exposure
-0.0007694845102255405
VIX.INDX Exposure
0.02172797085337042
UUP.US Exposure
0.026099229651436323
TIP.US Exposure
0.0005211835257215812
Idiosyncratic Exposure
0.017208204658221923
Value Score
50
Growth Score
50
Profit Score
37.5
Health Score
23.6
Yield Score
0
Moat Score
40

Factor Risk Decomposition

Share of annualised volatility attributable to each macro factor.

Total Est. Vol
483.0%

FundamentalsiCompany financial health metrics: P/E valuation, dividend yield, Piotroski F-Score (9-point profitability signal), Altman Z-Score (bankruptcy risk proxy), and a radar chart across 6 fundamental dimensions. Note: ETFs may show N/A for some metrics.

Fundamental Dimensions

Core Valuation

P/E Ratio (TTM)P/E RatioPrice-to-Earnings ratio — the market price of a stock divided by its earnings per share, a key valuation measure.Click for full definition →N/A
Dividend YieldDividend YieldAnnual dividend paid per share divided by the current share price — expressed as a percentage income return.Click for full definition →0.00%
Market Cap$166.6M
Piotroski F-ScorePiotroski F-ScoreA 9-point scoring system evaluating a company's financial strength across profitability, leverage, and operating efficiency.Click for full definition →
9-point profitability signal
0.0/ 9
Weak
Altman Z-ScoreAltman Z-ScoreA bankruptcy prediction model that combines 5 financial ratios into a single score indicating financial distress risk.Click for full definition →
Bankruptcy risk proxy
1.18
Distress Zone
Income Simulation

Based on $10,000 initial investment.

Total Income Generated
$0
Avg Yield on Cost
0.00%

Momentum & MacroiPrice momentum indicators relative to key technical levels: distance from 50-Day SMA (intermediate trend), 200-Day SMA (long-term trend), 52-Week High (bullish proximity), and Beta (market sensitivity coefficient).

vs 50-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+112.2%
Above/below 50-day moving average
vs 200-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+203.6%
Above/below 200-day moving average
vs 52-Week High52-Week HighThe highest price an asset reached in the past 52 weeks — a key reference for momentum and valuation context.Click for full definition →
0.0% from high
Distance from 52-week high
BetaBetaA measure of an asset's sensitivity to broad market movements relative to a benchmark (e.g. S&P 500).Click for full definition →
1.00
Market sensitivity coefficient

Frequently Asked Questions & Methodology

Is Artiva Biotherapeutics, Inc. Common Stock a high-risk investment?

Artiva Biotherapeutics, Inc. Common Stock (ARTV.US) has an annualized volatility of 483.0% and experienced a maximum drawdown of 90.2% over the last 10 years. Its primary macro risk driver is LQD.US.

What is the 10-year return of ARTV.US?

Over the past 10 years, ARTV.US has generated a Compound Annual Growth Rate (CAGR) of 1.5%. It has had a positive return in 50% of the years measured.

Data Methodology & Trust

The risk and return information on this page is pre-calculated mathematically using daily market data spanning a 10-year period. Fundamentals (such as P/E Ratio, Market Cap, and Dividend Yield) represent trailing averages and may not immediately reflect real-time live market fluctuations. Advanced scoring models like the Piotroski F-Score and Altman Z-Score are proxies applied to publicly available trailing-twelve-month financial statements and may not account for recent off-balance-sheet events, qualitative company shifts, or sector-specific capital structures. Macroeconomic factor exposures are estimated via multivariate regression against standard market indices. This data is provided for quantitative insight and backtesting research, and should not be misconstrued as tailored financial advice.

Run a Full Backtest on Artiva Biotherapeutics, Inc. Common Stock

stresstest.pro lets you simulate DCA vs Lump Sum, Monte Carlo projections, portfolio optimisation, and more — all in seconds.

Start a Free Backtest